CRMD.US CorMedix Inc

Healthcare Pharmaceuticals USA Stocks
4.66 USD
Close of Nov 14, 2026
4.65 13.02
Market cap
USD 370M
P/E
7.3x
P/B
0.83x
ROE
14.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRMD.US undervalued?

Graham number
Price4.66
Graham value8.97
Discount48.0%

CRMD.US trades 48.0% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

CorMedix Inc fundamental analysis

No fundamental analysis for CorMedix Inc yet.

CorMedix Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 200…

Full company profile